Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRB1ADRB2ADRB3CYP11B1DPP4FGFR1FGFR2FGFR3FGFR4HRH1JAK1JAK2JAK3KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITNAOPRD1OPRK1OPRM1PPDGFRBPIK3CDSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASMOTYK2polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pyrimidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.35 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | ALPI | P09923 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrimidine SCHEMBL988740 | 0.84 | FDPS (0.34) | FDPSBTN3A1PDE3AALPLALPI | |
| Pyrimidine SCHEMBL82718 | 0.84 | ALDH1A1 (0.33) | — | |
| Pyrimidine SCHEMBL4140222 | 0.84 | FDPS (0.34) | FDPSBTN3A1PDE3AALPLALPI | |
| Pyrimidine SCHEMBL4154828 | 0.84 | FDPS (0.34) | FDPSBTN3A1PDE3AALPLALPI | |
| Pyrimidine SCHEMBL454436 | 0.84 | FDPS (0.34) | FDPSBTN3A1PDE3AALPLALPI | |
| Triphosphate SCHEMBL153616 | 0.84 | FDPS (0.32) | FDPSBTN3A1PDE3A | |
| Phosphoric Acid SCHEMBL28225763 | 0.82 | FDPS (0.34) | FDPS | |
| Pyrimidine SCHEMBL28436619 | 0.82 | FDPS (0.33) | FDPSBTN3A1PDE3AALPLALPI | |
| Phosphoric Acid SCHEMBL9382169 | 0.82 | FDPS (0.37) | FDPS | |
| Phosphoric Acid SCHEMBL31619053 | 0.82 | FDPS (0.37) | FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1624059-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies, Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040086880-A1 | Method of producing nucleic acid molecules with reduced secondary structure | AGILENT TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | claimed |
| US-20250109449-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ROCHE SEQUENCING SOLUTIONS INC (US) | 2025-04-03 | — | — | US | disclosed |
| EP-2952587-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220064741-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2022-03-03 | — | — | US | disclosed |
| US-20180334729-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2018-11-22 | — | — | US | disclosed |
| US-9920386-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160208344-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2016-07-21 | — | — | US | disclosed |
| EP-2952587-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2171088-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20130172197-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8324360-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110251079-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-7939259-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| EP-2171088-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2009-02-05 | — | — | US | disclosed |
| WO-2008157696-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| EP-1624059-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies, Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20040086880-A1 | Method of producing nucleic acid molecules with reduced secondary structure | AGILENT TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109449-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, XPNPEP1 | FDPS 1897/4885BTN3A1 2074/4885PDE3A 4824/4885 |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | FDPS 1804/4885BTN3A1 2148/4885PDE3A 4867/4885 |
| US-20110237787-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | FDPS 1804/4885BTN3A1 2148/4885PDE3A 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.